| Document |
Document Title |
|
WO/2001/005443A1 |
The invention concerns a fluid adhesive protein foam, which is biocompatible, biologically absorbable and non-toxic, for surgical and/or therapeutic use, in particular for protecting/healing tissue wounds and for binding together biologi...
|
|
WO/2001/005790A1 |
The present invention relates to certain spirooxindole derivatives of formula (I), and pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are particulary effective in the treatment of chronic pain.
|
|
WO/2001/004297A2 |
The present invention provides human proteins having hydrophobic domains, DNAs encoding these proteins, expression vectors for these DNAs, transformed eukaryotic cells expressing these DNAs and antibodies directed to these proteins.
|
|
WO/2001/000246A2 |
The invention provides a polymeric structure comprising a multifunctional poly(alkylene oxide), such as a poly(ethylene glycol) derivative, covalently cross-linked to a polymer selected from the group consisting of chitosan and conjugate...
|
|
WO/2000/078259A1 |
The present invention describes the incorporation of liposomal gene constructs directly into a wound to further improve wound repair, or into wound coverage and/or closure materials to enhance the functionality of the material. The prese...
|
|
WO/2000/078776A2 |
2-Adenosine thiophene compounds having the formula (I): and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
|
|
WO/2000/076515A1 |
This invention relates to novel phenyl ureas useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2000/075107A2 |
Novel sulfonyl amine derivatives, of formula (IA) processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.
|
|
WO/2000/074682A1 |
Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have structure (I) or a pharmaceutically acceptable salt thereof, wherein A is (a), (b) or (c) whe...
|
|
WO/2000/072867A2 |
This invention provides composition comprising a cyclosporin and a carrier medium consisting of polyoxyethylene sorbitan fatty acid ester, a reaction product of a natural or hydrogenated castor oil and ethylene oxide, a sorbitan fatty ac...
|
|
WO/2000/067764A2 |
An improved method for treating or preventing a pathological condition in a mammalian subject in which modified mammalian blood is administered to the subject. The method comprises administering to the subject from two to four aliquots o...
|
|
WO/2000/067734A2 |
The invention relates to the use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP (EC 2.4.2.30), and to their use as inhibitors of PARP-homologous enzymes. These phthalazine derivatives also exhib...
|
|
WO/2000/067791A1 |
CCR4 receptor antagonists are used for treatment and/or prevention of sepsis and/or septic shock. The antagonists of this invention typically are selected among several classes but preferably are anti-CCR4 antibodies.
|
|
WO/2000/066086A1 |
Compositions and methods for systemically minimizing the inflammatory effects of TNF-$g(a) are disclosed. The compositions include particles of bioactive glass with a particle size less than about 20 $g(m)m, alone or in combination with ...
|
|
WO/2000/066130A1 |
The invention concerns a pharmaceutical composition containing in galenical unit form a combination of active principles with platelet antiaggregating activity consisting of acetylsalicylic acid and clopidogrel hydrogenosulphonate.
|
|
WO/2000/064468A2 |
The present inventors have surprisingly found that the Mts-1 protein stimulates angiogenesis. In particular, the present inventors have found that Mts-1 transgenic mice developed hemangiomas and stenosis. The present inventors have also ...
|
|
WO/2000/064930A2 |
The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
|
|
WO/2000/061755A2 |
Fifteen secreted human proteins and full-length cDNA sequences encoding the proteins have been identified. The proteins have various potential uses as therapeutics, such as for stimulating blood cell generation in patients receiving canc...
|
|
WO/2000/061620A1 |
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for p...
|
|
WO/2000/061204A1 |
The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelia...
|
|
WO/2000/058466A2 |
The invention relates to FLINT analogs that are resistant to proteolysis $i(in vivo) and $i(in vitro) at amino acid position 218 of mature FLINT, clinical and therapeutic uses thereof, and pharmaceutical formulations comprising said anal...
|
|
WO2000033822A9 |
The invention relates to an active ingredient matrix in the form of a biologically resorbable porous non-woven made of collagen fibrils in a dry frozen state with delayed release of said active ingredients. The matrix contains at least o...
|
|
WO/2000/056349A1 |
Methods for treating fibrosis in a mammal are described. An antifibrotic effective amount of a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr is administered to t...
|
|
WO/2000/056767A1 |
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for p...
|
|
WO/2000/056283A1 |
Polymeric compositions and devices for reducing or inhibiting the undesired effects or activity of matrix metalloproteinases (MMPs) in the body. Suitable devices include stents, catheters, guidewires, implants, or similar devices having ...
|
|
WO/2000/054757A2 |
Pirenoxine or 1-hydroxy-5-oxo-5H-pyrido-[3,2a]-phenoxazin-3-carboxylic acid, also called pirfenossone and already used as anti-cataract agent, in the form of a pharmaceutically acceptable salt thereof, if desired, is used for the protect...
|
|
WO/2000/054762A2 |
Angiogenesis is inhibited by the local administration of a pharmaceutical preparation formed from the reaction of hyaluronic acid, carboxymethylcellulose and a carbodiimide. The preparation, which can be in the form of a film or a gel, i...
|
|
WO/2000/050453A1 |
The present invention provides a human apoptosis regulator protein (Aven) and polynucleotides which identify and encode Aven. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic aci...
|
|
WO/2000/050040A1 |
A method comprising the use of a prostaglandin of subtype A or J for the prevention of scar formation in the filtration bleb and drainage fistula after glaucoma surgery is described. Compositions containing a prostaglandin of subtype A o...
|
|
WO/2000/046253A1 |
The present invention relates to a process for the production of cross-linked hyaluronic acid (HA) derivatives, in particular multiple, e.g. double cross-linked hyaluronic acid derivatives. The invention also provides novel cross-linked ...
|
|
WO/2000/045804A2 |
A method for the prevention or reduction in the severity of abscess formation in a human subject involves the use of a dilute solution of a polyanionic polysaccharide, preferably a solution of hyaluronic acid or carboxymethyl cellulose, ...
|
|
WO/2000/044371A1 |
The use of a compound of formula (1), wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5? and R¿6? are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R¿1? to R¿4...
|
|
WO2000012683A9 |
A composition of substantially purified pluripotent stem cells are positive both for fibroblast growth factor receptor (FGFR) and a phenotype indicative of a primitive state, such as CD34<+>, CD34<->lin<->, Thy-1<+>, AC133<+> or c-kit<+>...
|
|
WO/2000/042054A1 |
This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O- isopropylidene-$g(a) -L-xylo-2- hexulofuranosonic acid, of formula (I) compounds of this invention are useful, inter-alia, for the inhibit...
|
|
WO/2000/042031A2 |
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1, 3-thiazolidines, 2-arylimino-2, 3, 4, 5-tetrahydro-1, 3-thiazines, 2-arylimino-1, 3-thiazolidin-4-ones, 2-arylimino-1, 3-thiazolidin-5-ones, and 2-arylimino-1, ...
|
|
WO/2000/040742A1 |
The invention relates to a nuclear transport agent, to a gene transfer system comprising said nuclear transport agent, to a method of transporting DNA into the nucleus of eukaryotic cells using said nuclear transport agent and to the use...
|
|
WO/2000/038717A2 |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and a matrix metalloproteinase inhibitor.
|
|
WO2000011147A9 |
The invention provides a swine which is homozygous for a major histocompatibility complex haplotype and at least 60 % homozygous at all other genetic loci and such animal is propagatable, and a cell or an organ derived therefrom. The inv...
|
|
WO/2000/038719A1 |
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor, an integrin antagonist and an antineoplastic agent.
|
|
WO/2000/038718A2 |
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.
|
|
WO/2000/039087A2 |
This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula (I): wherein X is O, S or NR?1¿ which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition...
|
|
WO/2000/038786A2 |
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor, an integrin antagonist and an antineoplastic agent.
|
|
WO/2000/038715A2 |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
WO/2000/038665A2 |
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
|
|
WO/2000/038730A2 |
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor and an antineoplastic agent.
|
|
WO/2000/037025A2 |
The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interf...
|
|
WO/2000/037107A2 |
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor, a matrix metalloproteinase inhibitor and an antineoplastic agent.
|
|
WO/2000/035420A2 |
Improved stability surgical irrigating solutions and methods of use are disclosed. The compositions comprise bifunctional compounds (i.e., compounds comprising antioxidant and antiinflammatory moieties) and physiological antioxidants to ...
|
|
WO/2000/032577A2 |
Novel compounds of formula (I) in which R, R?1¿ and R?2¿ have the meaning indicated, and their salts or solvates as glycoprotein IbIX antagonists.
|
|
WO/2000/025745A2 |
A method an solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes at least one soluble receptor ...
|
